Costs of care for persons with opioid dependence in commercial integrated health systems

Addiction Science and Clinical Practice

Volumn 9, Issue 1, 2014, Pages

  Lynch, Frances L ^a   McCarty, Dennis ^b   Mertens, Jennifer ^c   Perrin, Nancy A ^a   Green, Carla A ^a   Parthasarathy, Sujaya ^c   Dickerson, John F ^a   Anderson, Bradley M ^d   Pating, David ^d  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DIVISION OF RESEARCH   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Commercial health insurance; Cost analysis; Health care utilization; Parity; Substance abuse

Indexed keywords

BUPRENORPHINE;

ADULT; ARTICLE; COHORT ANALYSIS; COMMERCIAL PHENOMENA; COMPARATIVE STUDY; COST OF ILLNESS; COUNSELING; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OPIATE ADDICTION; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADULT; BUPRENORPHINE; COHORT STUDIES; COMBINED MODALITY THERAPY; COMMERCE; COST OF ILLNESS; COUNSELING; DELIVERY OF HEALTH CARE, INTEGRATED; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; RETROSPECTIVE STUDIES; UNITED STATES; UTILIZATION REVIEW;

EID: 84907722062     PISSN: 19400632     EISSN: 19400640     Source Type: Journal    
DOI: 10.1186/1940-0640-9-16     Document Type: Article

References (26)

1. Mark TL, Woody GE, Juday T, Kleber HD: The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001, 61 (2): 195-206.
2. Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP: Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain. 2006, 22 (8): 667-676.
3. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007, 11 (9): 1-171. iii-iv
4. McCabe SE, Cranford JA, West BT: Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008, 33 (10): 1297-1305.
5. Weisner C, Parthasarathy S, Moore C, Mertens JR: Individuals receiving addiction treatment: are medical costs of their family members reduced?. Addiction. 2010, 105 (7): 1226-1234.
6. Ray GT, Mertens JR, Weisner C: Family members of people with alcohol or drug dependence: health problems and medical cost compared to family members of people with diabetes and asthma. Addiction. 2009, 104 (2): 203-214.
7. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009, 8 (3): CD002209-doi:10.1002/14651858.CD002209.pub2
8. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008, 16 (2): CD002207-doi:10.1002/14651858.CD002207.pub3
9. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D, BHIVES Collaborative: Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011, 56 (Suppl 1): S83-S90.
10. Korthuis PT, Saha S, Chander G, McCarty D, Moore RD, Cohn JA, Sharp VL, Beach MC: Substance use and the quality of patient-provider communication in HIV clinics. AIDS Behav. 2011, 15: 832-841.
11. McCarty D, Frank RG, Denmead GC: Methadone maintenance and state Medicaid managed care programs. Milbank Q. 1999, 77: 341-362.
12. Barry CL, Huskamp HA: Moving beyond parity-mental health and addiction care under the ACA. N Engl J Med. 2011, 365 (11): 973-975.
13. Buck JA: The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Aff (Millwood). 2011, 30: 1402-1410.
14. Barnett PG: Comparison of costs and utilization among buprenorphine and methadone patients. Addiction. 2009, 104 (6): 982-992.
15. Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA: Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009, 99 (1-3): 132-140.
16. Clark RE, Samnaliev M, McGovern MP: Impact of substance use disorders on medical expenditures for Medicaid beneficiaries with behavioral health disorders. Psychiatr Serv. 2009, 60 (1): 35-42.
17. Clark RE, Samnaliev M, Baxter JD, Leung GY: The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011, 30 (8): 1425-1433.
18. Barnett PG, Rodgers JH, Bloch DA: A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001, 96: 683-690.
19. Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE: Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010, 105 (9): 1616-1624.
20. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J: Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003, 71: 295-302.
21. Harris AH, Gospodarevskaya E, Ritter AJ: A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005, 23: 77-91.
22. Hurtado AV, Greenlick MR: A disease classification system for analysis of medical care utilization, with a note on symptom classification. Health Serv Res. 1971, 6: 235-250.
23. Stuart EA, Lee BK, Leacy FP: Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J Clin Epidemiol. 2013, 66: S84-S90.
24. Green CA, McCarty D, Mertens J, Lynch FL, Hilde A, Firemark A, Weisner CM, Pating D, Anderson BM: A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J Subst Abuse Treat. 2014, 46: 390-401.
25. Austin PC: The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009, 29: 661-677.
26. Austin PC: An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011, 46: 399-424.